Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study

Ann Rheum Dis. 2021 Feb;80(2):1-2. doi: 10.1136/annrheumdis-2020-218243. Epub 2020 Jul 9.
No abstract available

Keywords: biological therapy; cytokines; immune system diseases; inflammation.

Publication types

  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • COVID-19 / immunology
  • COVID-19 / mortality
  • COVID-19 Drug Treatment*
  • Case-Control Studies
  • Female
  • Humans
  • Inflammation
  • Male
  • Middle Aged
  • Receptors, Interleukin-6 / immunology*
  • Retrospective Studies
  • SARS-CoV-2 / immunology*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • IL6R protein, human
  • Receptors, Interleukin-6
  • tocilizumab